Claire Kylander
Family · Austin, TXNPI 1003581166
Payments from drug & device makers
Across 175 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$1K
- AbbVie$608
- Astellas Pharma US Inc$485
- Mayne Pharma Commercial LLC$284
- Medtronic$238
- 180 Medical, Inc.$190
- plus $1K from 12 others
What the payments were for
- Food & beverage$3,975100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 80 | $1,102 |
| AbbVie | 23 | $608 |
| Astellas Pharma US Inc | 15 | $485 |
| Mayne Pharma Commercial LLC | 7 | $284 |
| Medtronic | 5 | $238 |
| 180 Medical, Inc. | 5 | $190 |
| Coloplast | 5 | $175 |
| Exeltis, USA Inc. | 10 | $152 |
| Boston Scientific | 2 | $137 |
| Convatec Inc. | 2 | $117 |
| Millicent US Inc | 7 | $112 |
| Axonics, Inc. | 2 | $91 |
| CMP Pharma, Inc. | 2 | $84 |
| Ascend Therapeutics US, LLC | 4 | $60 |
| Xeris Pharmaceuticals, Inc. | 1 | $48 |
| Myovant Sciences Inc. | 2 | $40 |
| Integra Lifesciences Corporation | 2 | $35 |
| Exact Sciences | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veozah$340
- INTERSTIM$142
- NEXTSTELLIS$122
- BOTOX$115
How this compares
$3,975 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 17 | $19,366 |
| GemtesaVibegron | 14 | $19,218 |
| Mirabegron ErMirabegron | 14 | $9,587 |
| Estradiol | 63 | $4,441 |
| ProgesteroneProgesterone, Micronized | 20 | $835 |
| Armour ThyroidThyroid,pork | 11 | $324 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 30 | $282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $485 | $19,36617 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $1,102 | $19,21814 claims |
| AbbVieArmour Thyroid | $608 | $32411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Austin
- Nirupama JeromeAustin$418K
- Jean ChenAustin$176K
- Monique MulvanyAustin$142K
- Barry HughesAustin$51K
- Eric PerezAustin$42K
- Chelsea CrillyAustin$36K
- Alexandra RossiAustin$35K
- Angelina DetmersAustin$33K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.